Related Experiment Video

Updated: Jul 16, 2025

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells
09:48

An Orthotopic Endometrial Cancer Model with Retroperitoneal Lymphadenopathy Made From In Vivo Propagated and Cultured VX2 Cells

Published on: September 12, 2019

8.1K

ceRNA networks in gynecological cancers progression and resistance

Shuqin Wu1, Baoshan Zhong1, Yuxin Yang1

  • 1Jiangxi Medical College, Nanchang University, Nanchang, China.

Journal of Drug Targeting
|September 19, 2023
PubMed

Insights

Competing endogenous RNAs (ceRNAs) are crucial in gynecological cancer progression and resistance. This review explores ceRNAs as potential therapeutic targets and predictive biomarkers for improved diagnosis and treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gynecological cancers represent a significant health burden for women worldwide.
  • Current diagnostic methods often face delays and misdiagnoses due to incomplete understanding of cancer development and lack of specific biomarkers.
  • MicroRNA (miRNA)-mediated mechanisms involving competing endogenous RNAs (ceRNAs) are increasingly recognized for their role in cancer.

Purpose of the Study:

  • To review the involvement of the ceRNA hypothesis in the progression and resistance of gynecological cancers.
  • To identify potential ceRNAs that can serve as therapeutic targets.
  • To explore the utility of ceRNAs as predictive biomarkers for gynecological malignancies.

Main Methods:

  • Comprehensive literature search on competing endogenous RNAs (ceRNAs) and gynecological cancers.
  • Analysis of studies investigating ceRNA networks in miRNA-mediated gene regulation.
  • Synthesis of evidence linking ceRNAs to cancer progression, treatment resistance, and diagnostic potential.

Main Results:

  • ceRNAs play a significant role in modulating gene expression across various cancer-related pathways in gynecological cancers.
  • Dysregulation of ceRNA networks is implicated in both the initiation and advancement of these malignancies.
  • Specific ceRNAs have demonstrated potential in influencing treatment response and disease outcomes.

Conclusions:

  • The ceRNA network is a critical regulatory mechanism in gynecological cancer.
  • Targeting ceRNAs offers a promising therapeutic strategy for overcoming treatment resistance.
  • ceRNAs hold potential as valuable biomarkers for early diagnosis and prognosis in gynecological cancers.
Keywords:
Gynecological cancerceRNA networkmiRNAncRNAresistancetarget

More Related Videos

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time14:25

Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time

Published on: May 20, 2014

17.4K
Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-107:59

Evaluating the Angiogenetic Properties of Ovarian Cancer Stem-Like Cells using the Three-Dimensional Co-Culture System, NICO-1

Published on: December 5, 2020

2.6K

Related Concept Videos

Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
6.4K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
381
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
5.0K